IP Library › Granted Patent US 11,970,498
Granted Patent B2
US 11,970,498 · App. 18/166,178 · Granted Apr 30, 2024

CDK2 inhibitors

Inventors: Douglas Wilson (Ayer, MA); Neil Bifulco, Jr. (Sudbury, MA); Natasja Brooijmans (Boston, MA); Joseph L. Kim (Wayland, MA); Philip D. Ramsden (Cambridge, MA); Richard Vargas (Cambridge, MA); Steven Mark Wenglowsky (Cambridge, MA)
Assignee: BLUEPRINT MEDICINES CORPORATION
C07D487/04C07D519/00C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,970,498
App. No.
18/166,178
Filed
Feb 8, 2023
Granted
Apr 30, 2024
Kind
B2
Examiner
YOO, SUN JAE
Art Unit
1621
USPC
514/249
Abstract

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

Claims (26)

1. A pharmaceutically acceptable salt of a compound selected from the group consisting of:

2. The salt of claim 1 , wherein the compound is

3. The salt of claim 1 , wherein the compound is

4. The salt of claim 1 , wherein the compound is

5. The salt of claim 1 , wherein the compound is

6. The salt of claim 1 , wherein the compound is selected from the group consisting of:

7. The salt of claim 1 , wherein the compound is

8. The salt of claim 1 , wherein the compound is

9. The salt of claim 1 , wherein the compound is

10. The salt of claim 1 , wherein the compound is

11. The salt of claim 1 , wherein the compound is

12. The salt of claim 1 , wherein the compound is

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a salt of claim 1 .

14. A compound selected from the group consisting of:

15. The compound of claim 14 , wherein the compound is

16. The compound of claim 14 , wherein the compound is

17. The compound of claim 14 , wherein the compound is

18. The compound of claim 14 , wherein the compound is

19. The compound of claim 14 selected from the group consisting of:

20. The compound of claim 14 , wherein the compound is

21. The compound of claim 14 , wherein the compound is

22. The compound of claim 14 , wherein the compound is

23. The compound of claim 14 , wherein the compound is

24. The compound of claim 14 , wherein the compound is

25. The compound of claim 14 , wherein the compound is

26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 14 .

Assignments (3)
RELEASE OF SECURITY INTEREST (REEL/FRAME 064748/0552) Recorded Jul 24, 2025
From: TAO TALENTS, LLC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 072249/0280 →
SECURITY INTEREST Recorded Aug 29, 2023
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 064748/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: WILSON, DOUGLAS; BIFULCO, NEIL, JR.; BROOIJMANS, NATASJA; KIM, JOSEPH L.; PEROLA, EMANUELE; RAMSDEN, PHILIP D.; VARGAS, RICHARD; WENGLOWSKY, STEVEN MARK
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 064680/0199 →
Continuity (3)
Continuation 17850453 · Jun 27, 2022
Provisional Application 63215901 · Jun 28, 2021
Related Publication 20230322791A1 · Oct 12, 2023
Cited By (2)
US 12,545,684 US 12,668,585